Tiny Apri­cus’ sur­vival strat­e­gy nixed for now by FDA re­jec­tion of erec­tile dys­func­tion ther­a­py, shares crater

A lit­tle less than two years af­ter tiny, San Diego-based Apri­cus Bio­sciences $APRI de­cid­ed to cut its staff and con­cen­trate the sur­vivors on an erec­tile dys­func­tion cream called Vi­taros, the mi­cro­cap out­fit has run in­to an­oth­er brick wall.

The FDA has hand­ed the com­pa­ny a for­mal re­jec­tion, which Apri­cus says was trig­gered by CMC ques­tions as well as “safe­ty con­cerns spe­cif­ic to the 2.5% con­cen­tra­tion of DDAIP.HCl con­tained in the cur­rent for­mu­la­tion.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER